Joint Annual Meeting of the European MASLD&EGIR Study Groups - Maastricht, The Netherlands, from 23 to 25 November 2026

We are pleased to announce that registration is now open for the Joint Annual Meeting of the European MASLD Study Group and the European Group for Insulin Resistance (EGIR, which will take place in Maastricht, The Netherlands, from 23 to 25 November 2026.)

The meeting will bring together leading clinicians and researchers to discuss the latest advances in insulin resistance, metabolic dysfunction-associated steatotic liver disease (MASLD), diabetes, obesity, and related cardiometabolic diseases.

Abstract Submission

Abstract Submission is open, and the deadline is October 16, 2026. Abstract submission form

We accept abstracts presenting original results in clinical and basic science. Abstracts reporting data already presented at national or international meetings in the year 2026 are also eligible, as well as research published no more than six months before submission.

Expected notification of abstract acceptance: October 30, 2026.
Three awards of €500 each will be assigned to the best oral presentations submitted by researchers under the age of 42: one for a study related to MASLD, one for a study on insulin resistance and cardiometabolic diseases, and one for the best research in the biological field, dedicated to the memory of Valter Lubrano.

Registration

Please use the link for registration fees and to register online: Registration form

Registration Fees

The online form is a pre-registration: registration is considered complete only upon payment of the fee, by wire transfer only.

Accomodation

Hotel rooms are available at a reduced conference rate until 23 October at the conference venue, so we recommend booking before then if you are planning to attend, using the following link:
https://www.minor-hotels.com/en/eventsweb/masld-egir-maastricht

Key speakers

Insulin–Glucagon Crosstalk and Metabolic Rewiring: Positioning the Liver at the Center

• Amalia Gastaldelli (Pisa, Italy)
  The Hepatic Nexus: Connecting Insulin Resistance, Glucagon Action, and MASLD
• Nicolai Wewer Albrechtsen (Copenhagen, Denmark)
  Glucagon Action on Lipid and Amino Acid Metabolism

Sex Dimorphism in MASLD and Metabolic Disorders

• Sara Della Torre (Milan, Italy)
  Sex Dimorphism in MASLD and Metabolic Disorders
• Paula Macedo (Lisbon, Portugal)
  Clinical Implications for Personalized Medicine

Dietary Drivers of MASLD: Sugars, Lipids, and Metabolic Dysfunction

• Martijn Brouwers (Maastricht, the Netherlands)
  Fructose, Lipogenesis, and Metabolic Dysfunction: Is Sugar the New Lipid?
• Ulf Risérus (Uppsala, Sweden)
  Seed Oils and MASLD: Toxic or Beneficial?

Nutrition in MASLD and Metabolic Health: From Dietary Patterns to Precision Approaches

• Ellen Blaak (Maastricht, the Netherlands)
  Nutrition in the Prevention of Cardiometabolic Risk: From Dietary Patterns to Precision Approaches
• Stijn Meijnikman (Amsterdam, the Netherlands)
  Aging Signals from the Gut in Steatotic Liver Disease

Technical Advances in MASLD research

• Silvia Sabatini (Pisa, Italy)
  Systems Modelling of Metabolic Diseases
• Carolin Schneider (Dresden, Germany)
  AI-Driven Disease Maps and Systems Biology in MASLD
• Jeanine Prompers (Maastricht, the Netherlands)
  Deuterium Metabolic Imaging: A New Window on Liver Metabolism in MASLD

MASLD in the Cardiometabolic Era: Mechanisms, Therapeutic Targets, and Future Therapies

• Bart Staels (Lille, France)
  Nuclear Receptors in Cardiometabolic Disease
• Sven Francque (Antwerp, Belgium)
  Cardiometabolic Effects of Anti-MASH Therapies: Implications for Treatment Algorithms

Inflammation–Metabolism Interactions in the Progression of MASLD

• Joel Haas (Lille, France)
  Adipose–Liver Crosstalk in Insulin Resistance
• Olivier Govaere (Leuven, Belgium)
  Inflammation–Metabolism Interactions in the Progression of MASLD

Organizing committee

Associate Prof. Ruth Meex, NUTRIM, Maastricht University

Associate Prof. Kristiaan Wouters, CARIM, Maastricht University

Prof. Amalia Gastaldelli, Chair of both the European MASLD Study Group and EGIR.

Lucrecia Mota, Scientific Secretariat, Pisa, Italy